Keywords
Last Name
Institution

NATALIA LAPTEVA

TitleAssistant Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pathology & Immunology
DivisionImmunology
AddressOne Baylor Plaza
Houston TX 77030
vCardDownload vCard
    Other Positions
    TitleAssistant Professor
    InstitutionBaylor College of Medicine
    DepartmentCenter for Cell & Gene Therapy
    DivisionCenter for Cell & Gene Therapy


    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Lapteva N, Parihar R, Rollins LA, Gee AP, Rooney CM. Large-Scale Culture and Genetic Modification of Human Natural Killer Cells for Cellular Therapy. Methods Mol Biol. 2016; 1441:195-202. PMID: 27177667.
      View in: PubMed
    2. Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015 Jan; 38(1):24-36. PMID: 25415285; PMCID: PMC4352951.
    3. Miller JS, Rooney CM, Curtsinger J, McElmurry R, McCullar V, Verneris MR, Lapteva N, McKenna D, Wagner JE, Blazar BR, Tolar J. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1252-7. PMID: 24816582; PMCID: PMC4099265.
    4. Ngo MC, Ando J, Leen AM, Ennamuri S, Lapteva N, Vera JF, Min-Venditti A, Mims MP, Heslop HE, Bollard CM, Gottschalk S, Rooney CM. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother. 2014 May; 37(4):193-203. PMID: 24714353; PMCID: PMC4133102.
    5. Lapteva N, Szmania SM, van Rhee F, Rooney CM. Clinical grade purification and expansion of natural killer cells. Crit Rev Oncog. 2014; 19(1-2):121-32. PMID: 24941378; PMCID: PMC4095851.
    6. Lapteva N, Durett AG, Sun J, Rollins LA, Huye LL, Fang J, Dandekar V, Mei Z, Jackson K, Vera J, Ando J, Ngo MC, Coustan-Smith E, Campana D, Szmania S, Garg T, Moreno-Bost A, Vanrhee F, Gee AP, Rooney CM. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 2012 Oct; 14(9):1131-43. PMID: 22900959; PMCID: PMC4787300.
    7. Rockey WM, Hernandez FJ, Huang SY, Cao S, Howell CA, Thomas GS, Liu XY, Lapteva N, Spencer DM, McNamara JO, Zou X, Chen SJ, Giangrande PH. Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther. 2011 Oct; 21(5):299-314. PMID: 22004414; PMCID: PMC3198747.
    8. Lapteva N, Vera JF. Optimization manufacture of virus- and tumor-specific T cells. Stem Cells Int. 2011; 2011:434392. PMID: 21915183; PMCID: PMC3170896.
    9. Chiou SH, Shahi P, Wagner RT, Hu H, Lapteva N, Seethammagari M, Sun SC, Levitt JM, Spencer DM. The E3 ligase c-Cbl regulates dendritic cell activation. EMBO Rep. 2011 Sep; 12(9):971-9. PMID: 21799517; PMCID: PMC3166462.
    10. Narayanan P, Lapteva N, Seethammagari M, Levitt JM, Slawin KM, Spencer DM. A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Invest. 2011 Apr; 121(4):1524-34. PMID: 21383499; PMCID: PMC3069772.
    11. Ramachandran IR, Song W, Lapteva N, Seethammagari M, Slawin KM, Spencer DM, Levitt JM. The phosphatase SRC homology region 2 domain-containing phosphatase-1 is an intrinsic central regulator of dendritic cell function. J Immunol. 2011 Apr 1; 186(7):3934-45. PMID: 21357539.
      View in: PubMed
    12. Lapteva N, Huang XF. CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther. 2010 May; 10(5):725-33. PMID: 20233026.
      View in: PubMed
    13. Lapteva N. Enhanced migration of human dendritic cells expressing inducible CD40. Methods Mol Biol. 2010; 651:79-87. PMID: 20686961.
      View in: PubMed
    14. Lapteva N, Aldrich M, Rollins L, Ren W, Goltsova T, Chen SY, Huang XF. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther. 2009 Sep; 17(9):1626-36. PMID: 19532135; PMCID: PMC2835257.
    15. Lapteva N, Aldrich M, Weksberg D, Rollins L, Goltsova T, Chen SY, Huang XF. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother. 2009 Feb-Mar; 32(2):145-56. PMID: 19238013; PMCID: PMC4146345.
    16. Lapteva N, Seethammagari MR, Hanks BA, Jiang J, Levitt JM, Slawin KM, Spencer DM. Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res. 2007 Nov 1; 67(21):10528-37. PMID: 17974997.
      View in: PubMed
    17. Park D, Lapteva N, Seethammagari M, Slawin KM, Spencer DM. An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol. 2006 Dec; 24(12):1581-90. PMID: 17143278.
      View in: PubMed
    18. Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther. 2005 Jan; 12(1):84-9. PMID: 15472715.
      View in: PubMed
    LAPTEVA's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _